
Adamas Pharmaceuticals, Inc. Net Debt 2011-2026 | ADMS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Adamas Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 58.3 M | 61.9 M | 62.5 M | 11.3 M | -23.7 M | -33.1 M | -61.4 M | -85.6 M | -59 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 62.5 M | -85.6 M | -7.64 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.63 | - | $ 1.08 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
ADMA Biologics
ADMA
|
-17.2 M | $ 16.54 | - | $ 3.94 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Apellis Pharmaceuticals
APLS
|
-311 M | $ 19.86 | - | $ 2.51 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.83 | - | $ 4.53 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 8.37 | - | $ 1.36 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Cabaletta Bio
CABA
|
-188 M | $ 3.43 | 5.54 % | $ 4.01 M | ||
|
ANI Pharmaceuticals
ANIP
|
166 M | $ 76.53 | - | $ 1.48 B | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-48 M | - | - | $ 521 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
-706 M | $ 24.69 | - | $ 3.02 B | ||
|
Citius Pharmaceuticals
CTXR
|
-2.99 M | $ 0.82 | - | $ 5.52 M | ||
|
Axsome Therapeutics
AXSM
|
-205 M | $ 164.08 | - | $ 8.16 B | ||
|
Champions Oncology
CSBR
|
-8.23 M | $ 6.0 | - | $ 82 M | ||
|
BridgeBio Pharma
BBIO
|
1.44 B | $ 66.54 | - | $ 12.7 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
Equillium
EQ
|
-22.4 M | $ 1.75 | -1.13 % | $ 60.8 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
Eton Pharmaceuticals
ETON
|
-10.8 M | $ 17.53 | - | $ 450 M | ||
|
Evogene Ltd.
EVGN
|
-3.44 M | $ 0.84 | - | $ 27.9 M | ||
|
Exelixis
EXEL
|
-282 M | $ 41.69 | - | $ 11.3 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
-23.8 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
-13.9 M | $ 2.81 | - | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
-1.3 B | $ 60.43 | - | $ 11.6 B |